The FDA solicited comments on these requirements in the notice of proposed rulemaking and has evaluated and responded to them in the preamble to the final rule.
( ( The ( FDA solicited ) ) ( ( ( ( ( comments ( on ( these requirements ) ) ) ( in ( ( the notice ) ( of ( proposed rulemaking ) ) ) ) ) and ) ( has ( ( ( ( ( evaluated and ) responded ) ( to them ) ) ( in ( the preamble ) ) ) ( to ( the ( final rule ) ) ) ) ) ) . ) )
(ROOT (S (NP (DT The) (NNP FDA) (NNP solicited)) (VP (VP (VBZ comments) (PP (IN on) (NP (DT these) (NNS requirements))) (PP (IN in) (NP (NP (DT the) (NN notice)) (PP (IN of) (NP (VBN proposed) (NN rulemaking)))))) (CC and) (VP (VBZ has) (VP (VBN evaluated) (CC and) (VBN responded) (PP (TO to) (NP (PRP them))) (PP (IN in) (NP (DT the) (NN preamble))) (PP (TO to) (NP (DT the) (JJ final) (NN rule)))))) (. .)))
The FDA did not seek out comments on these requirements regarding the proposed rulemaking.
( ( The FDA ) ( ( ( did not ) ( ( ( seek out ) comments ) ( on ( ( these requirements ) ( regarding ( the ( proposed rulemaking ) ) ) ) ) ) ) . ) )
(ROOT (S (NP (DT The) (NNP FDA)) (VP (VBD did) (RB not) (VP (VB seek) (PRT (RP out)) (NP (NNS comments)) (PP (IN on) (NP (NP (DT these) (NNS requirements)) (PP (VBG regarding) (NP (DT the) (VBN proposed) (NN rulemaking))))))) (. .)))